Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Ivabradine for treating chronic heart failure (TA267)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Rivaroxaban for treating chronic heart failure [ID1462]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years TS ID 10350Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2016
Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2022
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021